PF-07901801 is under clinical development by Pfizer and currently in Phase II for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase II drugs for Cutaneous T-Cell Lymphoma have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PF-07901801’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TTI-622 is under development for the treatment of relapsed and refractory multiple myeloma, acute myelocytic leukemia, relapsed and refractory lymphoma, indolent non-Hodgkin’s lymphoma, classic Hodgkin’s lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, peripheral T-cell lymphomas (PTCL) and cutaneous T-cell lymphoma, solid tumors and platinum-resistant epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC). It consists of the CD47-binding domain of human SIRP alpha linked to the Fc region of human immunoglobulin IgG4 that acts by targeting CD47. The drug candidate is administered through intravenous route. It is developed based on Stem cell technology.
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of PF-07901801’s drug-specific PTSR and LoA scores, buy the report here.